All In Biotech

Drug Trial Radar · NCT04152486

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Evaluation of a Heterologous, Two-dose Preventive Ebola Vaccine for Effectiveness and Safety in the Democratic Republic of the Congo

Last checked: Nov 19, 2026Latest source record: Nov 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

20,426

Actual

Start

Nov 14, 2019

Primary completion

Jan 31, 2022

Study completion Feb 28, 2022

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Epicentre; Ministère de la Santé de la RDC; Médecins Sans Frontières, France; Coalition for Epidemic Preparedness Innovations; Janssen Vaccines & Prevention B.V.; Public Health England
First posted
Nov 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 1 year
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single arm, open-label, non-randomized, interventional phase 3 study to measure safety and effectiveness of a heterologous, two dose preventative vaccine (Ad26. ZEBOV, MVA-BN®-Filo) against Ebola Virus Disease.

Conditions

  • Ebola Virus Disease

Interventions

  • Ad26.ZEBOV, MVA-BN-Filo vaccineBiological

    Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®. MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers and odds of vaccination status in Ebola Virus Diseases cases and in EVD-negative controls.Time frame: Through study completion, an average of 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • L'Institut National de Recherche Biomédicale RDC

    Kinshasa, Democratic Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.